An expiring FDA program designed to incentivize research in pediatric rare disease may see new life. The Pediatric Rare Disease Priority Review Voucher (RPD PRV) provides sponsors of granted new ...
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results